Niamh Madigan | 05/30/2012
With a population of 1.9 billion and a multi-medicine model, the reporting of adverse reactions in medicine in India is crucial. The pharmacovigilance programme was launched in India in 2010 to provide education about drug safety. Dr. Y.K Gupta, Co-ordinator of the national pharmacovigilance programme, India tells Pharma IQ how to overcome the obstacles to implemeting such a programme.
Have Your Say
Rate this feature and give us your feedback in...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
DigIT Pharma 2026 | AI Commercial, Medical & Patient Care
September 9 - 10, 2026
Berlin, Germany
Register Now |
View Agenda |
Learn More
Pharmaceutical Launch Excellence Summit US
September 30 - October 1 2026
Hyatt Regency Boston Harbor, Boston, US
Register Now |
View Agenda |
Learn More